NextCath


MARKET OPPORTUNITY

CLINICAL

  • Short-term catheters including peripheral venous catheters (PVC) and central venous catheters (CVC)

 

ADDRESSABLE MARKET1

  • 90% of inpatients receive a PVC
  • ~7 million patients receive a CVC annually
  • Total: All short-term vascular catheters ~$2B
  • Immediate: PVC’s ~$1B

 

CURRENT DEVICE LIMITATIONS

  • Catheter dislodgement leads to pain, increased costs and potentially more serious complications
  • Monitoring catheter patency and security is labor intensive
  • Separate catheter securement devices add complexity and cost to patient care
  

PAVMED SOLUTION

NEXTCATH

  • Self-anchoring, short-term catheters
  • Integrated semi-stiff helical portion
  • Resists forceful dislodgement while allowing it to be advanced/withdrawn with gentle rotation
  • Applicable to most, if not all, short-term catheters

 

MORE COST EFFECTIVE

  • Eliminate need for costly catheter securement devices
  • Decrease need for monitoring catheter security
  • Decrease number of labor-intensive re-insertions

 

FEWER COMPLICATIONS

  • More secure than traditional approaches
  • Decreases complications associated with dislodgement
  • Decreases endothelial trauma and thrombosis from by decreasing micro-motion



This product is in the development phase and has yet to receive regulatory approval.